.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality globally, necessitating the identification of novel molecular markers for early diagnosis and targeted therapy. Recent genomic and transcriptomic studies have highlighted the role of mitochondrial subunits in tumor biology. Specifically, research into NDUFA10 in lung adenocarcinoma has revealed its potential as a critical oncogenic driver that facilitates tumor progression and metastasis. This subunit of NADH:ubiquinone oxidoreductase (Complex I) appears to be a key downstream effector in signaling pathways that promote malignancy.
Expression analyses using large-scale databases like TCGA and TIMER have confirmed that NDUFA10 mRNA and protein levels are significantly upregulated in LUAD tissues compared to adjacent normal tissues. This elevation is not merely a bystander effect; rather, it correlates strongly with advanced clinical parameters. Patients with high NDUFA10 expression often present with advanced N stages (N2/N3) and higher pathological stages (III/IV). Furthermore, elevated levels are associated with a significant decrease in overall survival (OS) and first progression (FP) intervals, marking NDUFA10 as a robust biomarker for poor prognosis.
The role of NDUFA10 in lung adenocarcinoma extends to the regulation of cellular plasticity and movement. Gene Set Enrichment Analysis (GSEA) suggests that this gene is intricately involved in the WNT and Notch signaling pathways. Additionally, it appears to modulate the TGFβ pathway, which is a well-known regulator of the epithelial-mesenchymal transition (EMT). By facilitating EMT, NDUFA10 promotes the migration and invasion of cancer cells. In vitro experiments have demonstrated that silencing NDUFA10 via knockdown significantly inhibits cell proliferation, colony formation, and invasive capabilities, suggesting its potential as a therapeutic target.
Beyond its role in cell growth, NDUFA10 expression is linked to the tumor immune microenvironment. Studies indicate a correlation between high NDUFA10 levels and poor efficacy of anti-PD-1/PD-L1 antibody therapies. This suggests that mitochondrial metabolism may influence immune evasion in LUAD. Future research aims to further elucidate the crosstalk between NDUFA10, reactive oxygen species (ROS) production, and energy metabolism to develop more effective combinatorial treatment strategies for patients with advanced lung cancer.
High expression of NDUFA10 is a negative prognostic indicator. It is associated with shorter overall survival, advanced pathological stages, and a higher likelihood of lymph node metastasis in patients with lung adenocarcinoma.
While still in the experimental phase, in vitro studies show that silencing NDUFA10 suppresses the proliferation and migration of LUAD cells. This suggests that targeting NDUFA10 or its associated pathways (like WNT/Notch) could be a viable strategy for future therapies.
Elevated NDUFA10 levels have been associated with the best efficacy outcomes in some cohorts but also suggest resistance in others; primarily, it serves as a marker for altered immune infiltration and poorer response to standard anti-PD-1/PD-L1 treatments in advanced cases.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research identifies NDUFA10 as a key driver of metastasis in lung adenocarcinoma, correlating with poor prognosis and anti-PD-1/PD-L1 therapy resistance...
6 months ago
A breakthrough peer-reviewed study demonstrates that a sequential AI diagnosis system can mirror real-world clinical reasoning. By ordering stepwise tests and updating hypotheses dynamically, this multi-agent orchestrator achieved superior diagnostic accuracy while reducing investigative costs.
Today
A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
